Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JORGE TOMAS CASO

Allopathic & Osteopathic Physicians Family Medicine

NPI
1457308157
CMS profile
201338
Location
MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$11.57

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $11.57 1

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
GlaxoSmithKline, LLC. $11.57 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JORGE TOMAS CASO

NPI 1457308157 · CMS profile ID 201338

Allopathic & Osteopathic Physicians / Family Medicine

MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1457308157?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JORGE TOMAS CASO, NPI 1457308157, CMS profile ID 201338. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1457308157?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). JORGE TOMAS CASO, NPI 1457308157, CMS profile ID 201338. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1457308157?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
JORGE TOMAS CASO, NPI 1457308157, CMS profile ID 201338, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1457308157?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $11.57 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $11.5709/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738478165 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2020 $11.57 1
PY2022 $1,200.00 1
PY2023 $4,459.41 20
PY2024 $1,274.65 11
PY2025 $35.85 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2020, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2020 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $5,513,175.40 309
PY2024 Recipient $2,105.91 13
PY2024 Principal investigator $5,484,672.89 220
PY2023 Recipient $1,815.05 10
PY2023 Principal investigator $6,619,562.71 1,445
PY2022 Principal investigator $4,761,350.73 1,335
PY2021 Principal investigator $244,385.00 24
PY2019 Principal investigator $19,780.00 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

1,455 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $158,090.84 12/31/2023 Non-covered Recipient Entity
Suncoast Research Associates
A Phase 3 Randomized, Double-blind, Placebo-Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly with Influenza Vaccine in Adults 50 Years of Age or Older No dispute reported 06/30/2026 1042566803
Principal investigator 1 Novavax Inc $35,459.94 12/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1055264817
Principal investigator 1 ModernaTX, Inc. $194,763.70 12/22/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1041270717
Principal investigator 1 Janssen Research & Development, LLC $1,138.00 12/20/2023 Non-covered Recipient Entity
Suncoast Rsrch Associates Llc
70033093AFL3002 No dispute reported 06/30/2026 986109041
Principal investigator 1 ModernaTX, Inc. $105,636.79 12/20/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1041270731
Principal investigator 1 Janssen Research & Development, LLC $2,276.00 12/15/2023 Non-covered Recipient Entity
Suncoast Rsrch Associates Llc
70033093AFL3002 No dispute reported 06/30/2026 986109045
Principal investigator 1 ModernaTX, Inc. $2,996.55 12/15/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1041270787
Principal investigator 1 ModernaTX, Inc. $4,456.14 12/15/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1041270803
Principal investigator 1 ModernaTX, Inc. $589.95 12/14/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041268940
Principal investigator 1 ModernaTX, Inc. $945.20 12/14/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041268965
Principal investigator 1 ModernaTX, Inc. $9,500.00 12/14/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041268979
Principal investigator 1 ModernaTX, Inc. $2,000.00 12/14/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041269005
Principal investigator 1 ModernaTX, Inc. $589.95 12/14/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041269019
Principal investigator 1 ModernaTX, Inc. $589.95 12/14/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041269033
Principal investigator 1 ModernaTX, Inc. $589.95 12/14/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041269047
Principal investigator 1 ModernaTX, Inc. $589.95 12/14/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041269061
Principal investigator 1 ModernaTX, Inc. $589.95 12/14/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041269075
Principal investigator 1 ModernaTX, Inc. $589.95 12/14/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041269089
Principal investigator 1 ModernaTX, Inc. $945.20 12/14/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041269101
Principal investigator 1 ModernaTX, Inc. $589.95 12/14/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041269157
Principal investigator 1 ModernaTX, Inc. $589.95 12/14/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041269201
Principal investigator 1 ModernaTX, Inc. $589.95 12/14/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041269215
Principal investigator 1 ModernaTX, Inc. $589.95 12/14/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041269229
Principal investigator 1 ModernaTX, Inc. $589.95 12/14/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041269243
Principal investigator 1 ModernaTX, Inc. $589.95 12/14/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041269257
Principal investigator 1 ModernaTX, Inc. $589.95 12/14/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041269285
Principal investigator 1 ModernaTX, Inc. $589.95 12/14/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041269355
Principal investigator 1 ModernaTX, Inc. $945.20 12/14/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041269371
Principal investigator 1 ModernaTX, Inc. $589.95 12/14/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041269411
Principal investigator 1 ModernaTX, Inc. $589.95 12/14/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041269423
Principal investigator 1 ModernaTX, Inc. $589.95 12/14/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041269469
Principal investigator 1 ModernaTX, Inc. $589.95 12/14/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041269511
Principal investigator 1 ModernaTX, Inc. $589.95 12/14/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041269566
Principal investigator 1 GlaxoSmithKline, LLC. $7,065.19 12/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC
A PHASE 1, SINGLE-BLIND, SAFETY, REACTOGENICITY, AND IMMUNOGENICITY TR No dispute reported 06/30/2026 1127785697
Principal investigator 1 GlaxoSmithKline, LLC. $6,537.75 12/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC
A PHASE 1, SINGLE-BLIND, SAFETY, REACTOGENICITY, AND IMMUNOGENICITY TR No dispute reported 06/30/2026 1127785699
Principal investigator 1 GlaxoSmithKline, LLC. $1,532.18 12/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC
A PHASE 1, SINGLE-BLIND, SAFETY, REACTOGENICITY, AND IMMUNOGENICITY TR No dispute reported 06/30/2026 1127785701
Principal investigator 1 Janssen Research & Development, LLC $640.00 12/13/2023 Non-covered Recipient Entity
Suncoast Rsrch Associates Llc
70033093AFL3002 No dispute reported 06/30/2026 986109057
Principal investigator 1 SANOFI PASTEUR INC. $2,900.00 12/12/2023 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older No dispute reported 06/30/2026 1035894065
Principal investigator 1 Bavarian Nordic A/S $4,134.51 12/08/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 988692029
Principal investigator 1 Bavarian Nordic A/S $1,600.00 12/08/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 988692035
Principal investigator 1 SANOFI PASTEUR INC. $1,200.00 12/08/2023 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1035894039
Recipient SANOFI PASTEUR INC. $75.00 12/07/2023 Covered Recipient Physician A Phase I/IIa, randomized, observer-blind, placebo-controlled multi-arm study to evaluate the safety and immunogenicity of an RSV/hMPV mRNA vaccine candidate in adult participants aged 60 years and older No dispute reported 06/30/2026 1035886787
Recipient SANOFI PASTEUR INC. $50.00 12/07/2023 Covered Recipient Physician A Phase I/IIa, randomized, observer-blind, placebo-controlled multi-arm study to evaluate the safety and immunogenicity of an RSV/hMPV mRNA vaccine candidate in adult participants aged 60 years and older No dispute reported 06/30/2026 1035886797
Recipient SANOFI PASTEUR INC. $78.00 12/07/2023 Covered Recipient Physician A Phase I/IIa, randomized, observer-blind, placebo-controlled multi-arm study to evaluate the safety and immunogenicity of an RSV/hMPV mRNA vaccine candidate in adult participants aged 60 years and older No dispute reported 06/30/2026 1035886807
Principal investigator 1 ModernaTX, Inc. $8,591.05 12/06/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1041270773
Recipient SANOFI PASTEUR INC. $621.95 12/06/2023 Covered Recipient Physician A Phase I/IIa, randomized, observer-blind, placebo-controlled multi-arm study to evaluate the safety and immunogenicity of an RSV/hMPV mRNA vaccine candidate in adult participants aged 60 years and older No dispute reported 06/30/2026 1035886749
Recipient SANOFI PASTEUR INC. $279.00 12/06/2023 Covered Recipient Physician A Phase I/IIa, randomized, observer-blind, placebo-controlled multi-arm study to evaluate the safety and immunogenicity of an RSV/hMPV mRNA vaccine candidate in adult participants aged 60 years and older No dispute reported 06/30/2026 1035886759
Recipient SANOFI PASTEUR INC. $61.14 12/06/2023 Covered Recipient Physician A Phase I/IIa, randomized, observer-blind, placebo-controlled multi-arm study to evaluate the safety and immunogenicity of an RSV/hMPV mRNA vaccine candidate in adult participants aged 60 years and older No dispute reported 06/30/2026 1035886769
Recipient SANOFI PASTEUR INC. $110.39 12/06/2023 Covered Recipient Physician A Phase I/IIa, randomized, observer-blind, placebo-controlled multi-arm study to evaluate the safety and immunogenicity of an RSV/hMPV mRNA vaccine candidate in adult participants aged 60 years and older No dispute reported 06/30/2026 1035886777
Principal investigator 1 SANOFI PASTEUR INC. $16,373.94 12/01/2023 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1035894003
Principal investigator 1 ModernaTX, Inc. $56,972.35 11/29/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1041268887
Principal investigator 1 ModernaTX, Inc. $117,302.32 11/29/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1041270703
Principal investigator 1 Novavax Inc $15,631.50 11/29/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1055263823
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041266843
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041266857
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041266871
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041266887
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041266901
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041266915
Principal investigator 1 ModernaTX, Inc. $519.41 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041266927
Principal investigator 1 ModernaTX, Inc. $945.20 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041266941
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041266955
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041266969
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041266983
Principal investigator 1 ModernaTX, Inc. $519.41 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041266997
Principal investigator 1 ModernaTX, Inc. $519.41 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041267011
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041267039
Principal investigator 1 ModernaTX, Inc. $945.20 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041267053
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041267067
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041267081
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041267095
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041267107
Principal investigator 1 ModernaTX, Inc. $519.41 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041267123
Principal investigator 1 ModernaTX, Inc. $945.20 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041267137
Principal investigator 1 ModernaTX, Inc. $945.20 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041267151
Principal investigator 1 ModernaTX, Inc. $945.20 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041267167
Principal investigator 1 ModernaTX, Inc. $519.41 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041267181
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041267195
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041267213
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041267227
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041267241
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041267255
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041267269
Principal investigator 1 ModernaTX, Inc. $945.20 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041267283
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041267311
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041267325
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041267339
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041267353
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041267367
Principal investigator 1 ModernaTX, Inc. $945.20 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041267381
Principal investigator 1 ModernaTX, Inc. $945.20 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041267395
Principal investigator 1 ModernaTX, Inc. $519.41 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041267409
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041267423
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041267437
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041267451
Principal investigator 1 ModernaTX, Inc. $945.20 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041267465
Principal investigator 1 ModernaTX, Inc. $519.41 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041267479
Principal investigator 1 ModernaTX, Inc. $519.41 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041267523
Principal investigator 1 ModernaTX, Inc. $519.41 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041267537
Principal investigator 1 ModernaTX, Inc. $519.41 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041267553
Principal investigator 1 ModernaTX, Inc. $519.41 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041267567
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041267581
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041267597
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041267611
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041267625
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041267639
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041267654
Principal investigator 1 ModernaTX, Inc. $519.41 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041267669
Principal investigator 1 ModernaTX, Inc. $519.41 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041267697
Principal investigator 1 ModernaTX, Inc. $519.41 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041267711
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041267725
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041267743
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041267757
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041267771
Principal investigator 1 ModernaTX, Inc. $519.41 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041267785
Principal investigator 1 ModernaTX, Inc. $945.20 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041267799
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041267813
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041267829
Principal investigator 1 ModernaTX, Inc. $945.20 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041267845
Principal investigator 1 ModernaTX, Inc. $519.41 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041267857
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041267871
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041267885
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041267899
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041267913
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041267927
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041267941
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041267955
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041267969
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041267985
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041267999
Principal investigator 1 ModernaTX, Inc. $945.20 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041268013
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041268027
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041268041
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041268055
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041268069
Principal investigator 1 ModernaTX, Inc. $945.20 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041268083
Principal investigator 1 ModernaTX, Inc. $945.20 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041268099
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041268127
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041268141
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041268155
Principal investigator 1 ModernaTX, Inc. $519.41 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041268169
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041268185
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041268199
Principal investigator 1 ModernaTX, Inc. $519.41 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041268213
Principal investigator 1 ModernaTX, Inc. $945.20 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041268563
Principal investigator 1 ModernaTX, Inc. $519.41 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041268577
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041268591
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041268607
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041268621
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041268635
Principal investigator 1 ModernaTX, Inc. $519.41 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041268649
Principal investigator 1 ModernaTX, Inc. $945.20 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041268663
Principal investigator 1 ModernaTX, Inc. $945.20 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041268677
Principal investigator 1 ModernaTX, Inc. $519.41 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041268691
Principal investigator 1 ModernaTX, Inc. $945.20 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041268705
Principal investigator 1 ModernaTX, Inc. $519.41 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041268717
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041268729
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041268743
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041268757
Principal investigator 1 ModernaTX, Inc. $589.95 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041268771
Principal investigator 1 ModernaTX, Inc. $519.41 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041268781
Principal investigator 1 ModernaTX, Inc. $519.41 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041268793
Principal investigator 1 ModernaTX, Inc. $945.20 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041268807
Principal investigator 1 ModernaTX, Inc. $945.20 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041268819
Principal investigator 1 ModernaTX, Inc. $519.41 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041268837
Principal investigator 1 ModernaTX, Inc. $945.20 11/28/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041268849
Principal investigator 1 Janssen Research & Development, LLC $2,798.00 11/17/2023 Non-covered Recipient Entity
Suncoast Rsrch Associates Llc
70033093AFL3002 No dispute reported 06/30/2026 986109049
Principal investigator 1 Bavarian Nordic A/S $15,732.00 11/15/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 988691991
Principal investigator 1 Bavarian Nordic A/S $1,900.95 11/15/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 988691997
Principal investigator 1 ModernaTX, Inc. $10,000.00 11/14/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041267025
Principal investigator 1 ModernaTX, Inc. $2,500.00 11/14/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041267507
Principal investigator 1 SANOFI PASTEUR INC. $200.00 11/09/2023 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1035894017
Principal investigator 1 SANOFI PASTEUR INC. $9,900.00 11/09/2023 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1035894029
Principal investigator 1 ModernaTX, Inc. $8,958.00 11/08/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1041268913
Principal investigator 1 ModernaTX, Inc. $1,080.00 11/08/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1041268927
Principal investigator 1 ModernaTX, Inc. $8,615.46 11/01/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1041268901
Principal investigator 1 ModernaTX, Inc. $589.95 10/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041265367
Principal investigator 1 ModernaTX, Inc. $589.95 10/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041265381
Principal investigator 1 ModernaTX, Inc. $589.95 10/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041265397
Principal investigator 1 ModernaTX, Inc. $589.95 10/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041265411
Principal investigator 1 ModernaTX, Inc. $589.95 10/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041265427
Principal investigator 1 ModernaTX, Inc. $589.95 10/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041265441
Principal investigator 1 ModernaTX, Inc. $589.95 10/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041265455
Principal investigator 1 ModernaTX, Inc. $589.95 10/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041265469
Principal investigator 1 ModernaTX, Inc. $589.95 10/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041265483
Principal investigator 1 ModernaTX, Inc. $589.95 10/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041265497
Principal investigator 1 ModernaTX, Inc. $589.95 10/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041265511
Principal investigator 1 ModernaTX, Inc. $589.95 10/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041265525
Principal investigator 1 ModernaTX, Inc. $589.95 10/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041265539
Principal investigator 1 ModernaTX, Inc. $589.95 10/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041265591
Principal investigator 1 ModernaTX, Inc. $589.95 10/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041265635
Principal investigator 1 ModernaTX, Inc. $589.95 10/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041265649
Principal investigator 1 ModernaTX, Inc. $589.95 10/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041265663
Principal investigator 1 ModernaTX, Inc. $589.95 10/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041265895
Principal investigator 1 ModernaTX, Inc. $589.95 10/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041265951
Principal investigator 1 ModernaTX, Inc. $589.95 10/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041265965
Principal investigator 1 ModernaTX, Inc. $589.95 10/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041266041
Principal investigator 1 ModernaTX, Inc. $589.95 10/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041266055
Principal investigator 1 ModernaTX, Inc. $589.95 10/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041266067
Principal investigator 1 ModernaTX, Inc. $589.95 10/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041266097
Principal investigator 1 ModernaTX, Inc. $589.95 10/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041266125
Principal investigator 1 ModernaTX, Inc. $589.95 10/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041266151
Principal investigator 1 ModernaTX, Inc. $589.95 10/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041266166
Principal investigator 1 ModernaTX, Inc. $589.95 10/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041266267
Principal investigator 1 ModernaTX, Inc. $589.95 10/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041266283
Principal investigator 1 ModernaTX, Inc. $589.95 10/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041266297
Principal investigator 1 ModernaTX, Inc. $589.95 10/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041266353
Principal investigator 1 ModernaTX, Inc. $589.95 10/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041266367
Principal investigator 1 ModernaTX, Inc. $589.95 10/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041266383
Principal investigator 1 ModernaTX, Inc. $589.95 10/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041266397
Principal investigator 1 ModernaTX, Inc. $589.95 10/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041266453
Principal investigator 1 ModernaTX, Inc. $1,013.40 10/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041266468
Principal investigator 1 ModernaTX, Inc. $589.95 10/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041266571
Principal investigator 1 ModernaTX, Inc. $589.95 10/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041266601
Principal investigator 1 ModernaTX, Inc. $589.95 10/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041266756
Principal investigator 1 ModernaTX, Inc. $589.95 10/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041266801
Principal investigator 1 ModernaTX, Inc. $589.95 10/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041266817
Principal investigator 1 ModernaTX, Inc. $589.95 10/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041266829
Principal investigator 1 ModernaTX, Inc. $227.70 10/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1041268545
Principal investigator 1 ModernaTX, Inc. $1,340.00 10/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1041270583
Principal investigator 1 ModernaTX, Inc. $1,340.00 10/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1041270597
Principal investigator 1 ModernaTX, Inc. $1,022.15 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041263941
Principal investigator 1 ModernaTX, Inc. $2,479.07 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041263955
Principal investigator 1 ModernaTX, Inc. $1,022.15 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041263971
Principal investigator 1 ModernaTX, Inc. $1,022.15 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041263989
Principal investigator 1 ModernaTX, Inc. $1,022.15 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041264003
Principal investigator 1 ModernaTX, Inc. $519.41 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041264033
Principal investigator 1 ModernaTX, Inc. $2,479.07 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041264047
Principal investigator 1 ModernaTX, Inc. $2,149.73 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041264061
Principal investigator 1 ModernaTX, Inc. $519.41 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041264091
Principal investigator 1 ModernaTX, Inc. $1,022.15 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041264105
Principal investigator 1 ModernaTX, Inc. $1,022.15 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041264119
Principal investigator 1 ModernaTX, Inc. $1,022.15 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041264133
Principal investigator 1 ModernaTX, Inc. $1,022.15 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041264191
Principal investigator 1 ModernaTX, Inc. $519.41 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041264205
Principal investigator 1 ModernaTX, Inc. $519.41 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041264217
Principal investigator 1 ModernaTX, Inc. $2,149.73 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041264231
Principal investigator 1 ModernaTX, Inc. $519.41 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041264245
Principal investigator 1 ModernaTX, Inc. $1,022.15 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041264259
Principal investigator 1 ModernaTX, Inc. $1,022.15 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041264273
Principal investigator 1 ModernaTX, Inc. $519.41 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041264287
Principal investigator 1 ModernaTX, Inc. $519.41 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041264303
Principal investigator 1 ModernaTX, Inc. $519.41 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041264317
Principal investigator 1 ModernaTX, Inc. $519.41 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041264359
Principal investigator 1 ModernaTX, Inc. $519.41 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041264374
Principal investigator 1 ModernaTX, Inc. $1,022.15 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041264389
Principal investigator 1 ModernaTX, Inc. $1,022.15 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041264405
Principal investigator 1 ModernaTX, Inc. $519.41 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041264419
Principal investigator 1 ModernaTX, Inc. $2,149.73 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041264433
Principal investigator 1 ModernaTX, Inc. $519.41 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041264463
Principal investigator 1 ModernaTX, Inc. $1,022.15 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041264475
Principal investigator 1 ModernaTX, Inc. $1,022.15 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041264491
Principal investigator 1 ModernaTX, Inc. $2,149.73 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041264507
Principal investigator 1 ModernaTX, Inc. $2,149.73 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041264535
Principal investigator 1 ModernaTX, Inc. $519.41 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041264563
Principal investigator 1 ModernaTX, Inc. $519.41 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041264577
Principal investigator 1 ModernaTX, Inc. $519.41 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041264619
Principal investigator 1 ModernaTX, Inc. $519.41 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041264637
Principal investigator 1 ModernaTX, Inc. $1,678.28 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041264651
Principal investigator 1 ModernaTX, Inc. $2,149.73 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041264665
Principal investigator 1 ModernaTX, Inc. $2,149.73 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041264679
Principal investigator 1 ModernaTX, Inc. $1,678.28 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041264695
Principal investigator 1 ModernaTX, Inc. $519.41 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041264723
Principal investigator 1 ModernaTX, Inc. $519.41 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041264737
Principal investigator 1 ModernaTX, Inc. $519.41 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041264751
Principal investigator 1 ModernaTX, Inc. $2,149.73 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041264765
Principal investigator 1 ModernaTX, Inc. $2,149.73 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041264779
Principal investigator 1 ModernaTX, Inc. $1,022.15 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041264821
Principal investigator 1 ModernaTX, Inc. $1,188.88 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041264837
Principal investigator 1 ModernaTX, Inc. $1,022.15 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041264851
Principal investigator 1 ModernaTX, Inc. $519.41 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041264865
Principal investigator 1 ModernaTX, Inc. $1,022.15 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041264881
Principal investigator 1 ModernaTX, Inc. $1,022.15 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041264895
Principal investigator 1 ModernaTX, Inc. $2,149.73 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041264909
Principal investigator 1 ModernaTX, Inc. $2,149.73 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041264923
Principal investigator 1 ModernaTX, Inc. $519.41 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041264937
Principal investigator 1 ModernaTX, Inc. $519.41 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041264951
Principal investigator 1 ModernaTX, Inc. $1,022.15 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041264965
Principal investigator 1 ModernaTX, Inc. $2,149.73 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041264979
Principal investigator 1 ModernaTX, Inc. $519.41 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041265555
Principal investigator 1 ModernaTX, Inc. $596.36 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041265605
Principal investigator 1 ModernaTX, Inc. $519.41 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041265621
Principal investigator 1 ModernaTX, Inc. $1,022.15 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041265677
Principal investigator 1 ModernaTX, Inc. $2,149.73 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041265691
Principal investigator 1 ModernaTX, Inc. $519.41 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041265717
Principal investigator 1 ModernaTX, Inc. $519.41 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041265731
Principal investigator 1 ModernaTX, Inc. $519.41 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041265760
Principal investigator 1 ModernaTX, Inc. $519.41 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041265775
Principal investigator 1 ModernaTX, Inc. $519.41 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041265791
Principal investigator 1 ModernaTX, Inc. $1,022.15 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041265803
Principal investigator 1 ModernaTX, Inc. $519.41 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041265819
Principal investigator 1 ModernaTX, Inc. $2,149.73 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041265831
Principal investigator 1 ModernaTX, Inc. $2,149.73 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041265845
Principal investigator 1 ModernaTX, Inc. $519.41 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041265869
Principal investigator 1 ModernaTX, Inc. $1,022.15 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041265881
Principal investigator 1 ModernaTX, Inc. $519.41 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041265909
Principal investigator 1 ModernaTX, Inc. $519.41 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041265923
Principal investigator 1 ModernaTX, Inc. $2,149.73 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041265937
Principal investigator 1 ModernaTX, Inc. $519.41 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041265979
Principal investigator 1 ModernaTX, Inc. $1,022.15 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041265995
Principal investigator 1 ModernaTX, Inc. $2,149.73 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041266011
Principal investigator 1 ModernaTX, Inc. $519.41 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041266081
Principal investigator 1 ModernaTX, Inc. $596.36 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041266111
Principal investigator 1 ModernaTX, Inc. $519.41 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041266181
Principal investigator 1 ModernaTX, Inc. $519.41 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041266195
Principal investigator 1 ModernaTX, Inc. $519.41 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041266209
Principal investigator 1 ModernaTX, Inc. $1,022.15 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041266223
Principal investigator 1 ModernaTX, Inc. $519.41 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041266311
Principal investigator 1 ModernaTX, Inc. $2,149.73 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041266323
Principal investigator 1 ModernaTX, Inc. $519.41 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041266411
Principal investigator 1 ModernaTX, Inc. $519.41 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041266425
Principal investigator 1 ModernaTX, Inc. $1,022.15 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041266439
Principal investigator 1 ModernaTX, Inc. $519.41 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041266483
Principal investigator 1 ModernaTX, Inc. $519.41 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041266497
Principal investigator 1 ModernaTX, Inc. $596.36 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041266513
Principal investigator 1 ModernaTX, Inc. $519.41 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041266527
Principal investigator 1 ModernaTX, Inc. $519.41 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041266555
Principal investigator 1 ModernaTX, Inc. $519.41 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041266587
Principal investigator 1 ModernaTX, Inc. $519.41 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041266615
Principal investigator 1 ModernaTX, Inc. $1,188.88 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041266629
Principal investigator 1 ModernaTX, Inc. $519.41 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041266643
Principal investigator 1 ModernaTX, Inc. $2,479.07 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041266657
Principal investigator 1 ModernaTX, Inc. $519.41 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041266671
Principal investigator 1 ModernaTX, Inc. $2,479.07 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041266685
Principal investigator 1 ModernaTX, Inc. $2,149.73 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041266699
Principal investigator 1 ModernaTX, Inc. $519.41 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041266713
Principal investigator 1 ModernaTX, Inc. $2,479.07 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041266727
Principal investigator 1 ModernaTX, Inc. $2,149.73 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041266741
Principal investigator 1 ModernaTX, Inc. $2,479.07 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041266771
Principal investigator 1 ModernaTX, Inc. $1,022.15 10/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041266787
Principal investigator 1 Bavarian Nordic A/S $4,640.00 10/25/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC
Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults 65 Years No dispute reported 06/30/2026 988695213
Principal investigator 1 Janssen Research & Development, LLC $9,984.00 10/25/2023 Non-covered Recipient Entity
Suncoast Rsrch Associates Llc
70033093AFL3002 No dispute reported 06/30/2026 986109053
Principal investigator 1 ModernaTX, Inc. $124.00 10/23/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041248153
Principal investigator 1 ModernaTX, Inc. $204.00 10/20/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041248139
Principal investigator 1 Janssen Pharmaceuticals, Inc $3,057.00 10/18/2023 Non-covered Recipient Entity
Suncoast Rsrch Associates Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986093569
Principal investigator 1 ModernaTX, Inc. $1,500.00 10/16/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041265305
Principal investigator 1 Bavarian Nordic A/S $14,932.29 10/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 988691971
Principal investigator 1 ModernaTX, Inc. $519.41 10/06/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041263911
Principal investigator 1 ModernaTX, Inc. $519.41 10/06/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041263927
Principal investigator 1 ModernaTX, Inc. $519.41 10/06/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041264019
Principal investigator 1 ModernaTX, Inc. $519.41 10/06/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041264163
Principal investigator 1 ModernaTX, Inc. $519.41 10/06/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041264181
Principal investigator 1 ModernaTX, Inc. $519.41 10/06/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041264333
Principal investigator 1 ModernaTX, Inc. $519.41 10/06/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041264347
Principal investigator 1 ModernaTX, Inc. $519.41 10/06/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041264521
Principal investigator 1 ModernaTX, Inc. $519.41 10/06/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041264593
Principal investigator 1 ModernaTX, Inc. $519.41 10/06/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041264605
Principal investigator 1 ModernaTX, Inc. $519.41 10/06/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041264709
Principal investigator 1 ModernaTX, Inc. $519.41 10/06/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041264807
Principal investigator 1 ModernaTX, Inc. $519.41 10/06/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041264999
Principal investigator 1 ModernaTX, Inc. $519.41 10/06/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041265013
Principal investigator 1 ModernaTX, Inc. $519.41 10/06/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041265041
Principal investigator 1 ModernaTX, Inc. $519.41 10/06/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041265055
Principal investigator 1 ModernaTX, Inc. $519.41 10/06/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041265069
Principal investigator 1 ModernaTX, Inc. $519.41 10/06/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041265097
Principal investigator 1 ModernaTX, Inc. $519.41 10/06/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041265115
Principal investigator 1 ModernaTX, Inc. $519.41 10/06/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041265161
Principal investigator 1 ModernaTX, Inc. $519.41 10/06/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041265231
Principal investigator 1 ModernaTX, Inc. $519.41 10/06/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041265247
Principal investigator 1 ModernaTX, Inc. $519.41 10/06/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041265261
Principal investigator 1 ModernaTX, Inc. $519.41 10/06/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041265277
Principal investigator 1 ModernaTX, Inc. $519.41 10/06/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041265337
Principal investigator 1 ModernaTX, Inc. $519.41 10/06/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041265353
Principal investigator 1 Bavarian Nordic A/S $64,289.50 10/04/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 No dispute reported 06/30/2026 988695177
Principal investigator 1 ModernaTX, Inc. $124.00 10/03/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041248169
Principal investigator 1 Merck Sharp & Dohme LLC $120,845.00 10/02/2023 Non-covered Recipient Entity
Suncoast Research Associates
A Phase 3 Randomized, Double-blind, Placebo-Controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 When Administered Concomitantly with Influenza Vaccine in Adults 50 Years of Age or Older No dispute reported 06/30/2026 1042566793
Principal investigator 1 ModernaTX, Inc. $8,650.00 10/02/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041248183
Principal investigator 1 ModernaTX, Inc. $96.60 10/02/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041263423
Principal investigator 1 ModernaTX, Inc. $589.95 10/02/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041263451
Principal investigator 1 ModernaTX, Inc. $37,975.00 10/02/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041263465
Principal investigator 1 ModernaTX, Inc. $22,080.00 10/02/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041263479
Principal investigator 1 ModernaTX, Inc. $240.12 10/02/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041263493
Principal investigator 1 ModernaTX, Inc. $589.95 10/02/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041263579
Principal investigator 1 ModernaTX, Inc. $96.60 10/02/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041263593
Principal investigator 1 ModernaTX, Inc. $100.00 10/02/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041263623
Principal investigator 1 ModernaTX, Inc. $331.20 10/02/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041263653
Principal investigator 1 ModernaTX, Inc. $320.00 10/02/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041263681
Principal investigator 1 ModernaTX, Inc. $589.95 10/02/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041263695
Principal investigator 1 ModernaTX, Inc. $589.95 10/02/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041263709
Principal investigator 1 ModernaTX, Inc. $89.70 10/02/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041263723
Principal investigator 1 ModernaTX, Inc. $589.95 10/02/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041263737
Principal investigator 1 ModernaTX, Inc. $240.12 10/02/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041263751
Principal investigator 1 ModernaTX, Inc. $89.70 10/02/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041263765
Principal investigator 1 ModernaTX, Inc. $96.60 10/02/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041263781
Principal investigator 1 ModernaTX, Inc. $1,120.00 10/02/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041263795
Principal investigator 1 ModernaTX, Inc. $234.60 10/02/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041263809
Principal investigator 1 ModernaTX, Inc. $331.20 10/02/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041263825
Principal investigator 1 ModernaTX, Inc. $589.95 10/02/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041263841
Principal investigator 1 ModernaTX, Inc. $589.95 10/02/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041263855
Principal investigator 1 ModernaTX, Inc. $96.60 10/02/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041263869
Principal investigator 1 ModernaTX, Inc. $1,013.40 10/02/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041263883
Principal investigator 1 ModernaTX, Inc. $1,013.40 10/02/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041263897
Principal investigator 1 ModernaTX, Inc. $1,340.00 10/02/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1041270543
Principal investigator 1 ModernaTX, Inc. $6,360.00 10/02/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1041270555
Principal investigator 1 ModernaTX, Inc. $1,500.00 10/02/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1041270569
Principal investigator 1 ModernaTX, Inc. $375.00 10/02/2023 Non-covered Recipient Entity
CLINICAL BIOSAFETY SERVICES
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042060483
Principal investigator 1 Bavarian Nordic A/S $3,700.00 09/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 No dispute reported 06/30/2026 988695171
Principal investigator 1 Bavarian Nordic A/S $8,750.00 09/22/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination No dispute reported 06/30/2026 988692085
Principal investigator 1 Bavarian Nordic A/S $1,850.00 09/22/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination No dispute reported 06/30/2026 988692091
Principal investigator 1 Bavarian Nordic A/S $1,500.00 09/22/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination No dispute reported 06/30/2026 988692099
Principal investigator 1 Janssen Research & Development, LLC $2,371.00 09/22/2023 Non-covered Recipient Entity
Suncoast Rsrch Associates Llc
70033093AFL3002 No dispute reported 06/30/2026 986109037
Principal investigator 1 SANOFI PASTEUR INC. $31,259.34 09/22/2023 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1035893665
Principal investigator 1 SANOFI PASTEUR INC. $475.00 09/22/2023 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1035893753
Principal investigator 1 SANOFI PASTEUR INC. $865.00 09/22/2023 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1035893765
Principal investigator 1 ModernaTX, Inc. $204.00 09/20/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1041248125
Principal investigator 1 Bavarian Nordic A/S $36,013.17 09/15/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 988691069
Principal investigator 1 Janssen Research & Development, LLC $16,512.00 09/15/2023 Non-covered Recipient Entity
Suncoast Rsrch Associates Llc
70033093AFL3002 No dispute reported 06/30/2026 986109033
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041262479
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041262489
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041262503
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041262517
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041262531
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041262545
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041262561
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041262575
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041262589
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041262603
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041262617
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041262631
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041262645
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041262659
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041262673
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041262687
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041262701
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041262715
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041262731
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041262745
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041262761
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041262775
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041262789
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041262803
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041262817
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041262831
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041262847
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041262859
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041262875
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041262889
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041262905
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041262919
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041262935
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041262949
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041262963
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041262975
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041262989
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041263002
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041263015
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041263029
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041263047
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041263061
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041263077
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041263091
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041263105
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041263121
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041263135
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041263149
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041263163
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041263177
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041263191
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041263205
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041263219
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041263235
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041263249
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041263263
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041263277
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041263293
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041263309
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041263323
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041263335
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041263349
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041263363
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041263379
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041263395
Principal investigator 1 ModernaTX, Inc. $589.95 09/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041263409
Principal investigator 1 ModernaTX, Inc. $1,340.00 09/08/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1041270513
Principal investigator 1 Janssen Pharmaceuticals, Inc $1,900.00 09/06/2023 Non-covered Recipient Entity
Suncoast Rsrch Associates Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986093563
Principal investigator 1 ModernaTX, Inc. $2,149.73 09/06/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041261955
Principal investigator 1 ModernaTX, Inc. $2,149.73 09/06/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041261969
Principal investigator 1 ModernaTX, Inc. $1,950.94 09/06/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041261983
Principal investigator 1 ModernaTX, Inc. $1,950.94 09/06/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041262013
Principal investigator 1 ModernaTX, Inc. $2,149.73 09/06/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041262028
Principal investigator 1 ModernaTX, Inc. $1,678.28 09/06/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041262041
Principal investigator 1 ModernaTX, Inc. $1,950.94 09/06/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041262055
Principal investigator 1 ModernaTX, Inc. $2,149.73 09/06/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041262071
Principal investigator 1 ModernaTX, Inc. $1,950.94 09/06/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041262099
Principal investigator 1 ModernaTX, Inc. $1,950.94 09/06/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041262113
Principal investigator 1 ModernaTX, Inc. $1,950.94 09/06/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041262127
Principal investigator 1 ModernaTX, Inc. $1,950.94 09/06/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041262143
Principal investigator 1 ModernaTX, Inc. $1,950.94 09/06/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041262157
Principal investigator 1 ModernaTX, Inc. $2,149.73 09/06/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041262171
Principal investigator 1 ModernaTX, Inc. $2,149.73 09/06/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041262187
Principal investigator 1 ModernaTX, Inc. $1,950.94 09/06/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041262215
Principal investigator 1 ModernaTX, Inc. $665.62 09/06/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041262231
Principal investigator 1 ModernaTX, Inc. $1,950.94 09/06/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041262261
Principal investigator 1 ModernaTX, Inc. $1,950.94 09/06/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041262289
Principal investigator 1 ModernaTX, Inc. $2,149.73 09/06/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041262303
Principal investigator 1 ModernaTX, Inc. $1,950.94 09/06/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041262331
Principal investigator 1 ModernaTX, Inc. $2,149.73 09/06/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041262345
Principal investigator 1 ModernaTX, Inc. $2,149.73 09/06/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041262373
Principal investigator 1 ModernaTX, Inc. $1,950.94 09/06/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041262417
Principal investigator 1 ModernaTX, Inc. $2,149.73 09/06/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041262431
Principal investigator 1 ModernaTX, Inc. $2,149.73 09/06/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041262447
Principal investigator 1 ModernaTX, Inc. $2,149.73 09/06/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041262463
Principal investigator 1 ModernaTX, Inc. $1,340.00 09/06/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1041270499
Principal investigator 1 Bavarian Nordic A/S $300.00 08/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 988691871
Principal investigator 1 GlaxoSmithKline, LLC. $10,265.92 08/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
A PHASE 1, SINGLE-BLIND, SAFETY, REACTOGENICITY, AND IMMUNOGENICITY TR No dispute reported 06/30/2026 1006174319
Principal investigator 1 GlaxoSmithKline, LLC. $1,485.89 08/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
A PHASE 1, SINGLE-BLIND, SAFETY, REACTOGENICITY, AND IMMUNOGENICITY TR No dispute reported 06/30/2026 1006174357
Principal investigator 1 GlaxoSmithKline, LLC. $41,108.42 08/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
A PHASE 1, SINGLE-BLIND, SAFETY, REACTOGENICITY, AND IMMUNOGENICITY TR No dispute reported 06/30/2026 1006174393
Principal investigator 1 GlaxoSmithKline, LLC. $1,407.10 08/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC
A PHASE 1, SINGLE-BLIND, SAFETY, REACTOGENICITY, AND IMMUNOGENICITY TR No dispute reported 06/30/2026 1006174905
Principal investigator 1 SANOFI PASTEUR INC. $20,082.48 08/30/2023 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1035893613
Principal investigator 1 SANOFI PASTEUR INC. $1,225.00 08/30/2023 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1035893777
Principal investigator 1 SANOFI PASTEUR INC. $100.00 08/30/2023 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1035893801
Principal investigator 1 SANOFI PASTEUR INC. $100.00 08/29/2023 Non-covered Recipient Entity
Suncoast Research Associates Llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035893809
Principal investigator 1 SANOFI PASTEUR INC. $186.30 08/29/2023 Non-covered Recipient Entity
Suncoast Research Associates Llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035893833
Principal investigator 1 SANOFI PASTEUR INC. $475.00 08/29/2023 Non-covered Recipient Entity
Suncoast Research Associates Llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035893847
Principal investigator 1 SANOFI PASTEUR INC. $532.68 08/29/2023 Non-covered Recipient Entity
Suncoast Research Associates Llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035893875
Principal investigator 1 SANOFI PASTEUR INC. $634.80 08/29/2023 Non-covered Recipient Entity
Suncoast Research Associates Llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035893899
Principal investigator 1 SANOFI PASTEUR INC. $865.00 08/29/2023 Non-covered Recipient Entity
Suncoast Research Associates Llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035893937
Principal investigator 1 SANOFI PASTEUR INC. $66,491.85 08/28/2023 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1035893699
Principal investigator 1 Bavarian Nordic A/S $77,727.31 08/25/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 988691853
Principal investigator 1 Bavarian Nordic A/S $49,461.56 08/25/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 988691859
Principal investigator 1 Bavarian Nordic A/S $44,485.75 08/25/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 988691865
Principal investigator 1 Bavarian Nordic A/S $17,375.86 08/25/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC
Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults 65 Years No dispute reported 06/30/2026 988695041
Principal investigator 1 GlaxoSmithKline, LLC. $2,081.21 08/25/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
A PHASE 1, SINGLE-BLIND, SAFETY, REACTOGENICITY, AND IMMUNOGENICITY TR No dispute reported 06/30/2026 1006174381
Principal investigator 1 SANOFI PASTEUR INC. $300.00 08/24/2023 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1035893789
Principal investigator 1 SANOFI PASTEUR INC. $400.00 08/24/2023 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1035893824
Principal investigator 1 SANOFI PASTEUR INC. $400.00 08/24/2023 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1035893859
Principal investigator 1 SANOFI PASTEUR INC. $400.00 08/24/2023 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1035893913
Principal investigator 1 Bavarian Nordic A/S $42,161.76 08/23/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 988691063
Principal investigator 1 Bavarian Nordic A/S $400.00 08/23/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 988691077
Principal investigator 1 Bavarian Nordic A/S $400.00 08/23/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 988692189
Principal investigator 1 Bavarian Nordic A/S $400.00 08/23/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 988692193
Principal investigator 1 Bavarian Nordic A/S $41,045.76 08/17/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC
Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults 65 Years No dispute reported 06/30/2026 988695035
Principal investigator 1 ModernaTX, Inc. $1,500.00 08/16/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1041270399
Principal investigator 1 ModernaTX, Inc. $6,695.00 08/16/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1041270413
Principal investigator 1 SANOFI PASTEUR INC. $12,721.15 08/15/2023 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older No dispute reported 06/30/2026 1035893639
Principal investigator 1 ModernaTX, Inc. $1,340.00 08/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1041270372
Principal investigator 1 ModernaTX, Inc. $1,340.00 08/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1041270385
Principal investigator 1 Janssen Pharmaceuticals, Inc $475.00 08/07/2023 Non-covered Recipient Entity
Suncoast Rsrch Associates Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986093567
Principal investigator 1 ModernaTX, Inc. $2,275.00 08/04/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041261881
Principal investigator 1 ModernaTX, Inc. $16,695.00 08/04/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041261909
Principal investigator 1 ModernaTX, Inc. $3,080.00 08/04/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041261923
Principal investigator 1 ModernaTX, Inc. $10,040.00 08/04/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041261941
Recipient Novavax Inc $166.57 08/04/2023 Covered Recipient Physician A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1055258329
Recipient Novavax Inc $182.03 08/04/2023 Covered Recipient Physician A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1055258331
Recipient Novavax Inc $190.97 08/04/2023 Covered Recipient Physician A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1055258513
Principal investigator 1 Janssen Pharmaceuticals, Inc $4,080.00 08/02/2023 Non-covered Recipient Entity
Suncoast Rsrch Associates Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986093565
Principal investigator 1 ModernaTX, Inc. $9,640.00 08/01/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041261839
Principal investigator 1 ModernaTX, Inc. $2,880.00 08/01/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041261853
Principal investigator 1 ModernaTX, Inc. $15,855.00 08/01/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041261867
Principal investigator 1 ModernaTX, Inc. $1,400.00 08/01/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041261895
Principal investigator 1 SANOFI PASTEUR INC. $2,977.08 07/27/2023 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1035893677
Principal investigator 1 Janssen Pharmaceuticals, Inc $2,316.00 07/21/2023 Non-covered Recipient Entity
Suncoast Rsrch Associates Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986093561
Principal investigator 1 Bavarian Nordic A/S $32,499.69 07/19/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 988691057
Principal investigator 1 Bavarian Nordic A/S $33,621.54 07/19/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC
Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults 65 Years No dispute reported 06/30/2026 988695055
Principal investigator 1 Bavarian Nordic A/S $60,453.26 07/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC
Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults 65 Years No dispute reported 06/30/2026 988695029
Principal investigator 1 ModernaTX, Inc. $1,224.08 07/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1041268489
Principal investigator 1 Bavarian Nordic A/S $78,520.88 07/10/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC
Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults 65 Years No dispute reported 06/30/2026 988695047
Principal investigator 1 SANOFI PASTEUR INC. $10,250.00 07/04/2023 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1035893563
Principal investigator 1 SANOFI PASTEUR INC. $1,925.00 07/04/2023 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1035893577
Principal investigator 1 SANOFI PASTEUR INC. $2,625.00 07/04/2023 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1035893625
Principal investigator 1 SANOFI PASTEUR INC. $45,509.30 07/04/2023 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1035893689
Principal investigator 1 ModernaTX, Inc. $1,188.88 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041256745
Principal investigator 1 ModernaTX, Inc. $596.36 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041256761
Principal investigator 1 ModernaTX, Inc. $2,479.07 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041256773
Principal investigator 1 ModernaTX, Inc. $1,891.69 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041256789
Principal investigator 1 ModernaTX, Inc. $596.36 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041258195
Principal investigator 1 ModernaTX, Inc. $596.36 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041258209
Principal investigator 1 ModernaTX, Inc. $2,479.07 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041258223
Principal investigator 1 ModernaTX, Inc. $2,479.07 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041258237
Principal investigator 1 ModernaTX, Inc. $1,891.69 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041258251
Principal investigator 1 ModernaTX, Inc. $1,188.88 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041258265
Principal investigator 1 ModernaTX, Inc. $596.36 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041258281
Principal investigator 1 ModernaTX, Inc. $1,188.88 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041258295
Principal investigator 1 ModernaTX, Inc. $1,188.88 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041258311
Principal investigator 1 ModernaTX, Inc. $596.36 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041258325
Principal investigator 1 ModernaTX, Inc. $2,479.07 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041258339
Principal investigator 1 ModernaTX, Inc. $1,891.69 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041258355
Principal investigator 1 ModernaTX, Inc. $1,188.88 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041258371
Principal investigator 1 ModernaTX, Inc. $1,891.69 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041258383
Principal investigator 1 ModernaTX, Inc. $1,188.88 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041258397
Principal investigator 1 ModernaTX, Inc. $596.36 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041258411
Principal investigator 1 ModernaTX, Inc. $2,479.07 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041258425
Principal investigator 1 ModernaTX, Inc. $1,891.69 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041258441
Principal investigator 1 ModernaTX, Inc. $1,188.88 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041258455
Principal investigator 1 ModernaTX, Inc. $596.36 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041258467
Principal investigator 1 ModernaTX, Inc. $2,479.07 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041258481
Principal investigator 1 ModernaTX, Inc. $1,891.69 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041258495
Principal investigator 1 ModernaTX, Inc. $1,188.88 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041258511
Principal investigator 1 ModernaTX, Inc. $596.36 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041258525
Principal investigator 1 ModernaTX, Inc. $596.36 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041258541
Principal investigator 1 ModernaTX, Inc. $2,479.07 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041258553
Principal investigator 1 ModernaTX, Inc. $1,891.69 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041258567
Principal investigator 1 ModernaTX, Inc. $1,891.69 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041258583
Principal investigator 1 ModernaTX, Inc. $596.36 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041258597
Principal investigator 1 ModernaTX, Inc. $596.36 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041258611
Principal investigator 1 ModernaTX, Inc. $2,479.07 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041258625
Principal investigator 1 ModernaTX, Inc. $1,891.69 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041258639
Principal investigator 1 ModernaTX, Inc. $1,188.88 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041258653
Principal investigator 1 ModernaTX, Inc. $2,479.07 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041258671
Principal investigator 1 ModernaTX, Inc. $596.36 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041258685
Principal investigator 1 ModernaTX, Inc. $2,479.07 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041258699
Principal investigator 1 ModernaTX, Inc. $1,891.69 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041258711
Principal investigator 1 ModernaTX, Inc. $1,188.88 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041258725
Principal investigator 1 ModernaTX, Inc. $596.36 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041258739
Principal investigator 1 ModernaTX, Inc. $2,479.07 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041258757
Principal investigator 1 ModernaTX, Inc. $1,891.69 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041258771
Principal investigator 1 ModernaTX, Inc. $1,891.69 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041258783
Principal investigator 1 ModernaTX, Inc. $1,188.88 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041258799
Principal investigator 1 ModernaTX, Inc. $596.36 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041258813
Principal investigator 1 ModernaTX, Inc. $2,479.07 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041258829
Principal investigator 1 ModernaTX, Inc. $1,891.69 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041258843
Principal investigator 1 ModernaTX, Inc. $1,188.88 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041258857
Principal investigator 1 ModernaTX, Inc. $596.36 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041258871
Principal investigator 1 ModernaTX, Inc. $2,479.07 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041258887
Principal investigator 1 ModernaTX, Inc. $1,891.69 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041258903
Principal investigator 1 ModernaTX, Inc. $1,188.88 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041258917
Principal investigator 1 ModernaTX, Inc. $1,188.88 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041258931
Principal investigator 1 ModernaTX, Inc. $596.36 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041258945
Principal investigator 1 ModernaTX, Inc. $2,479.07 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041258959
Principal investigator 1 ModernaTX, Inc. $2,479.07 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041258973
Principal investigator 1 ModernaTX, Inc. $1,891.69 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041258988
Principal investigator 1 ModernaTX, Inc. $1,188.88 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041259003
Principal investigator 1 ModernaTX, Inc. $596.36 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041259017
Principal investigator 1 ModernaTX, Inc. $2,479.07 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041259032
Principal investigator 1 ModernaTX, Inc. $1,891.69 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041259047
Principal investigator 1 ModernaTX, Inc. $1,188.88 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041259061
Principal investigator 1 ModernaTX, Inc. $1,891.69 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041259075
Principal investigator 1 ModernaTX, Inc. $1,188.88 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041259089
Principal investigator 1 ModernaTX, Inc. $596.36 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041259105
Principal investigator 1 ModernaTX, Inc. $2,479.07 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041259119
Principal investigator 1 ModernaTX, Inc. $1,891.69 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041259133
Principal investigator 1 ModernaTX, Inc. $1,188.88 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041259147
Principal investigator 1 ModernaTX, Inc. $596.36 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041259161
Principal investigator 1 ModernaTX, Inc. $596.36 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041259177
Principal investigator 1 ModernaTX, Inc. $2,479.07 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041259191
Principal investigator 1 ModernaTX, Inc. $1,891.69 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041259205
Principal investigator 1 ModernaTX, Inc. $1,188.88 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041259219
Principal investigator 1 ModernaTX, Inc. $596.36 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041259233
Principal investigator 1 ModernaTX, Inc. $2,479.07 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041259247
Principal investigator 1 ModernaTX, Inc. $1,891.69 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041259261
Principal investigator 1 ModernaTX, Inc. $1,188.88 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041259275
Principal investigator 1 ModernaTX, Inc. $596.36 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041259289
Principal investigator 1 ModernaTX, Inc. $2,479.07 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041259305
Principal investigator 1 ModernaTX, Inc. $1,891.69 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041259319
Principal investigator 1 ModernaTX, Inc. $2,479.07 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041259333
Principal investigator 1 ModernaTX, Inc. $1,891.69 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041259347
Principal investigator 1 ModernaTX, Inc. $1,188.88 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041259361
Principal investigator 1 ModernaTX, Inc. $2,479.07 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041259377
Principal investigator 1 ModernaTX, Inc. $2,479.07 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041259391
Principal investigator 1 ModernaTX, Inc. $1,891.69 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041259405
Principal investigator 1 ModernaTX, Inc. $596.36 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041259419
Principal investigator 1 ModernaTX, Inc. $1,188.88 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041259433
Principal investigator 1 ModernaTX, Inc. $2,479.07 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041259447
Principal investigator 1 ModernaTX, Inc. $2,479.07 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041259461
Principal investigator 1 ModernaTX, Inc. $1,891.69 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041259475
Principal investigator 1 ModernaTX, Inc. $1,188.88 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041259489
Principal investigator 1 ModernaTX, Inc. $2,479.07 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041259503
Principal investigator 1 ModernaTX, Inc. $1,891.69 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041259517
Principal investigator 1 ModernaTX, Inc. $1,891.69 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041259531
Principal investigator 1 ModernaTX, Inc. $1,188.88 06/30/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041259546
Principal investigator 1 SANOFI PASTEUR INC. $60,825.21 06/27/2023 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1035893273
Principal investigator 1 Bavarian Nordic A/S $260,084.18 06/21/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 988691051
Principal investigator 1 Bavarian Nordic A/S $74,878.86 06/21/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC
Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults 65 Years No dispute reported 06/30/2026 988695023
Principal investigator 1 SANOFI PASTEUR INC. $8,989.28 06/13/2023 Non-covered Recipient Entity
Suncoast Research Associates Llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035893237
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041253993
Principal investigator 1 ModernaTX, Inc. $4,508.63 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254011
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254023
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254037
Principal investigator 1 ModernaTX, Inc. $1,950.94 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254051
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254065
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254079
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254095
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254109
Principal investigator 1 ModernaTX, Inc. $4,508.63 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254121
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254135
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254147
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254163
Principal investigator 1 ModernaTX, Inc. $761.80 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254177
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254191
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254205
Principal investigator 1 ModernaTX, Inc. $665.62 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254217
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254237
Principal investigator 1 ModernaTX, Inc. $1,950.94 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254253
Principal investigator 1 ModernaTX, Inc. $761.80 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254267
Principal investigator 1 ModernaTX, Inc. $2,991.05 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254281
Principal investigator 1 ModernaTX, Inc. $665.62 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254293
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254307
Principal investigator 1 ModernaTX, Inc. $1,950.94 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254321
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254339
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254353
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254367
Principal investigator 1 ModernaTX, Inc. $4,508.63 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254379
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254395
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254409
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254421
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254435
Principal investigator 1 ModernaTX, Inc. $761.80 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254449
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254463
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254479
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254495
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254507
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254521
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254535
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254549
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254563
Principal investigator 1 ModernaTX, Inc. $761.80 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254577
Principal investigator 1 ModernaTX, Inc. $4,508.63 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254591
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254605
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254619
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254633
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254645
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254655
Principal investigator 1 ModernaTX, Inc. $4,508.63 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254667
Principal investigator 1 ModernaTX, Inc. $4,508.63 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254681
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254697
Principal investigator 1 ModernaTX, Inc. $4,508.63 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254711
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254723
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254739
Principal investigator 1 ModernaTX, Inc. $4,508.63 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254753
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254765
Principal investigator 1 ModernaTX, Inc. $665.62 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254779
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254795
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254809
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254823
Principal investigator 1 ModernaTX, Inc. $761.80 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254837
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254853
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254867
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254881
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254893
Principal investigator 1 ModernaTX, Inc. $665.62 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254907
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254921
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254937
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254951
Principal investigator 1 ModernaTX, Inc. $1,950.94 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254965
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254979
Principal investigator 1 ModernaTX, Inc. $761.80 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041254993
Principal investigator 1 ModernaTX, Inc. $4,508.63 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255009
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255023
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255037
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255051
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255065
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255079
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255093
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255107
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255121
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255135
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255305
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255319
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255333
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255347
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255361
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255379
Principal investigator 1 ModernaTX, Inc. $4,508.63 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255393
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255407
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255421
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255435
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255449
Principal investigator 1 ModernaTX, Inc. $4,508.63 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255463
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255479
Principal investigator 1 ModernaTX, Inc. $4,508.63 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255491
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255505
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255523
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255537
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255551
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255565
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255579
Principal investigator 1 ModernaTX, Inc. $4,508.63 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255593
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255609
Principal investigator 1 ModernaTX, Inc. $665.62 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255623
Principal investigator 1 ModernaTX, Inc. $1,950.94 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255639
Principal investigator 1 ModernaTX, Inc. $4,508.63 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255653
Principal investigator 1 ModernaTX, Inc. $4,508.63 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255667
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255683
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255697
Principal investigator 1 ModernaTX, Inc. $665.62 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255711
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255725
Principal investigator 1 ModernaTX, Inc. $4,508.63 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255739
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255755
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255771
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255785
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255804
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255818
Principal investigator 1 ModernaTX, Inc. $4,508.63 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255831
Principal investigator 1 ModernaTX, Inc. $761.80 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255845
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255861
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255871
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255887
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255905
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255917
Principal investigator 1 ModernaTX, Inc. $1,950.94 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255933
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255947
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255961
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255975
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041255989
Principal investigator 1 ModernaTX, Inc. $4,508.63 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256001
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256019
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256033
Principal investigator 1 ModernaTX, Inc. $4,508.63 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256047
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256061
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256075
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256087
Principal investigator 1 ModernaTX, Inc. $665.62 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256101
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256115
Principal investigator 1 ModernaTX, Inc. $1,950.94 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256131
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256145
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256159
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256173
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256187
Principal investigator 1 ModernaTX, Inc. $761.80 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256201
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256215
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256229
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256245
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256261
Principal investigator 1 ModernaTX, Inc. $665.62 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256275
Principal investigator 1 ModernaTX, Inc. $1,950.94 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256289
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256303
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256317
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256331
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256345
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256361
Principal investigator 1 ModernaTX, Inc. $4,508.63 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256375
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256391
Principal investigator 1 ModernaTX, Inc. $665.62 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256405
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256419
Principal investigator 1 ModernaTX, Inc. $665.62 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256433
Principal investigator 1 ModernaTX, Inc. $4,508.63 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256447
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256461
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256475
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256489
Principal investigator 1 ModernaTX, Inc. $4,508.63 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256505
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256517
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256531
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256547
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256563
Principal investigator 1 ModernaTX, Inc. $4,508.63 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256577
Principal investigator 1 ModernaTX, Inc. $761.80 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256591
Principal investigator 1 ModernaTX, Inc. $4,508.63 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256603
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256617
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256631
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256647
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256661
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256675
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256687
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256703
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256717
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256731
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256805
Principal investigator 1 ModernaTX, Inc. $4,508.63 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256821
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256835
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256849
Principal investigator 1 ModernaTX, Inc. $761.80 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256863
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256877
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256891
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256907
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256921
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256935
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256951
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256965
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256979
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041256993
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257009
Principal investigator 1 ModernaTX, Inc. $2,862.54 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257021
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257039
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257053
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257067
Principal investigator 1 ModernaTX, Inc. $761.80 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257081
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257095
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257109
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257123
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257137
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257151
Principal investigator 1 ModernaTX, Inc. $665.62 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257167
Principal investigator 1 ModernaTX, Inc. $4,508.63 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257181
Principal investigator 1 ModernaTX, Inc. $1,950.94 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257195
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257211
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257225
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257241
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257253
Principal investigator 1 ModernaTX, Inc. $4,508.63 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257269
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257283
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257297
Principal investigator 1 ModernaTX, Inc. $761.80 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257311
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257327
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257341
Principal investigator 1 ModernaTX, Inc. $4,508.63 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257357
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257371
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257387
Principal investigator 1 ModernaTX, Inc. $665.62 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257401
Principal investigator 1 ModernaTX, Inc. $1,950.94 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257415
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257430
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257445
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257459
Principal investigator 1 ModernaTX, Inc. $1,950.94 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257473
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257487
Principal investigator 1 ModernaTX, Inc. $1,950.94 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257503
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257517
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257531
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257545
Principal investigator 1 ModernaTX, Inc. $761.80 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257559
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257575
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257589
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257603
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257617
Principal investigator 1 ModernaTX, Inc. $761.80 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257631
Principal investigator 1 ModernaTX, Inc. $4,508.63 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257645
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257661
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257675
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257691
Principal investigator 1 ModernaTX, Inc. $761.80 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257703
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257717
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257731
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257747
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257761
Principal investigator 1 ModernaTX, Inc. $4,508.63 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257775
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257789
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257803
Principal investigator 1 ModernaTX, Inc. $761.80 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257819
Principal investigator 1 ModernaTX, Inc. $665.62 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257833
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257849
Principal investigator 1 ModernaTX, Inc. $1,950.94 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257863
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257877
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257893
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257907
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257921
Principal investigator 1 ModernaTX, Inc. $761.80 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257935
Principal investigator 1 ModernaTX, Inc. $761.80 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257951
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257965
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257979
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041257993
Principal investigator 1 ModernaTX, Inc. $4,508.63 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041258007
Principal investigator 1 ModernaTX, Inc. $665.62 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041258021
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041258035
Principal investigator 1 ModernaTX, Inc. $1,950.94 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041258049
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041258063
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041258077
Principal investigator 1 ModernaTX, Inc. $761.80 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041258095
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041258109
Principal investigator 1 ModernaTX, Inc. $761.80 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041258123
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041258137
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041258151
Principal investigator 1 ModernaTX, Inc. $19.24 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041258165
Principal investigator 1 ModernaTX, Inc. $4,508.63 06/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041258181
Principal investigator 1 ModernaTX, Inc. $96.60 06/09/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041255145
Principal investigator 1 ModernaTX, Inc. $6,405.00 06/09/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041255161
Principal investigator 1 ModernaTX, Inc. $13,240.00 06/09/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041255175
Principal investigator 1 ModernaTX, Inc. $16,835.00 06/09/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041255187
Principal investigator 1 ModernaTX, Inc. $2,760.00 06/09/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041255201
Principal investigator 1 ModernaTX, Inc. $89.70 06/09/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041255215
Principal investigator 1 ModernaTX, Inc. $96.60 06/09/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041255227
Principal investigator 1 ModernaTX, Inc. $234.60 06/09/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041255243
Principal investigator 1 ModernaTX, Inc. $193.20 06/09/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041255257
Principal investigator 1 ModernaTX, Inc. $331.20 06/09/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041255271
Principal investigator 1 ModernaTX, Inc. $240.12 06/09/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041255291
Principal investigator 1 ModernaTX, Inc. $2,121.00 06/01/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1041268475
Principal investigator 1 ModernaTX, Inc. $5,360.00 05/29/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253937
Principal investigator 1 ModernaTX, Inc. $16,590.00 05/29/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253951
Principal investigator 1 SANOFI PASTEUR INC. $203,943.84 05/29/2023 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1035893209
Principal investigator 1 ModernaTX, Inc. $86,802.45 05/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1041268373
Principal investigator 1 Bavarian Nordic A/S $6,148.59 05/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 988691045
Principal investigator 1 ModernaTX, Inc. $7,315.00 05/22/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253893
Principal investigator 1 ModernaTX, Inc. $9,280.00 05/22/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253907
Principal investigator 1 ModernaTX, Inc. $2,765.00 05/22/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253921
Principal investigator 1 ModernaTX, Inc. $4,480.00 05/22/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253965
Principal investigator 1 Bavarian Nordic A/S $55,309.78 05/19/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 988691037
Principal investigator 1 ModernaTX, Inc. $589.95 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252867
Principal investigator 1 ModernaTX, Inc. $589.95 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252881
Principal investigator 1 ModernaTX, Inc. $589.95 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252897
Principal investigator 1 ModernaTX, Inc. $589.95 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252911
Principal investigator 1 ModernaTX, Inc. $589.95 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252939
Principal investigator 1 ModernaTX, Inc. $1,013.40 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252953
Principal investigator 1 ModernaTX, Inc. $589.95 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252967
Principal investigator 1 ModernaTX, Inc. $1,013.40 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252981
Principal investigator 1 ModernaTX, Inc. $589.95 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252995
Principal investigator 1 ModernaTX, Inc. $589.95 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253009
Principal investigator 1 ModernaTX, Inc. $589.95 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253037
Principal investigator 1 ModernaTX, Inc. $589.95 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253065
Principal investigator 1 ModernaTX, Inc. $589.95 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253081
Principal investigator 1 ModernaTX, Inc. $589.95 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253095
Principal investigator 1 ModernaTX, Inc. $589.95 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253109
Principal investigator 1 ModernaTX, Inc. $1,013.40 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253123
Principal investigator 1 ModernaTX, Inc. $589.95 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253137
Principal investigator 1 ModernaTX, Inc. $589.95 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253173
Principal investigator 1 ModernaTX, Inc. $1,013.40 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253187
Principal investigator 1 ModernaTX, Inc. $1,013.40 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253197
Principal investigator 1 ModernaTX, Inc. $589.95 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253211
Principal investigator 1 ModernaTX, Inc. $589.95 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253221
Principal investigator 1 ModernaTX, Inc. $589.95 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253233
Principal investigator 1 ModernaTX, Inc. $589.95 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253247
Principal investigator 1 ModernaTX, Inc. $1,013.40 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253273
Principal investigator 1 ModernaTX, Inc. $589.95 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253283
Principal investigator 1 ModernaTX, Inc. $589.95 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253297
Principal investigator 1 ModernaTX, Inc. $589.95 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253311
Principal investigator 1 ModernaTX, Inc. $589.95 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253333
Principal investigator 1 ModernaTX, Inc. $589.95 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253345
Principal investigator 1 ModernaTX, Inc. $1,013.40 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253359
Principal investigator 1 ModernaTX, Inc. $589.95 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253373
Principal investigator 1 ModernaTX, Inc. $589.95 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253385
Principal investigator 1 ModernaTX, Inc. $589.95 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253399
Principal investigator 1 ModernaTX, Inc. $589.95 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253413
Principal investigator 1 ModernaTX, Inc. $1,013.40 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253427
Principal investigator 1 ModernaTX, Inc. $1,013.40 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253441
Principal investigator 1 ModernaTX, Inc. $589.95 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253455
Principal investigator 1 ModernaTX, Inc. $589.95 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253469
Principal investigator 1 ModernaTX, Inc. $589.95 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253483
Principal investigator 1 ModernaTX, Inc. $589.95 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253497
Principal investigator 1 ModernaTX, Inc. $589.95 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253511
Principal investigator 1 ModernaTX, Inc. $589.95 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253525
Principal investigator 1 ModernaTX, Inc. $1,013.40 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253539
Principal investigator 1 ModernaTX, Inc. $1,013.40 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253567
Principal investigator 1 ModernaTX, Inc. $1,013.40 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253581
Principal investigator 1 ModernaTX, Inc. $589.95 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253595
Principal investigator 1 ModernaTX, Inc. $1,013.40 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253609
Principal investigator 1 ModernaTX, Inc. $589.95 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253623
Principal investigator 1 ModernaTX, Inc. $589.95 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253637
Principal investigator 1 ModernaTX, Inc. $589.95 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253651
Principal investigator 1 ModernaTX, Inc. $589.95 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253679
Principal investigator 1 ModernaTX, Inc. $589.95 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253693
Principal investigator 1 ModernaTX, Inc. $589.95 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253709
Principal investigator 1 ModernaTX, Inc. $589.95 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253723
Principal investigator 1 ModernaTX, Inc. $589.95 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253735
Principal investigator 1 ModernaTX, Inc. $589.95 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253749
Principal investigator 1 ModernaTX, Inc. $589.95 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253763
Principal investigator 1 ModernaTX, Inc. $589.95 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253777
Principal investigator 1 ModernaTX, Inc. $589.95 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253793
Principal investigator 1 ModernaTX, Inc. $1,013.40 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253807
Principal investigator 1 ModernaTX, Inc. $589.95 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253821
Principal investigator 1 ModernaTX, Inc. $589.95 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253835
Principal investigator 1 ModernaTX, Inc. $1,013.40 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253849
Principal investigator 1 ModernaTX, Inc. $1,013.40 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253865
Principal investigator 1 ModernaTX, Inc. $589.95 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253879
Principal investigator 1 ModernaTX, Inc. $589.95 05/18/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253979
Principal investigator 1 ModernaTX, Inc. $89.70 05/17/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252925
Principal investigator 1 ModernaTX, Inc. $240.12 05/17/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253023
Principal investigator 1 ModernaTX, Inc. $96.60 05/17/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253051
Principal investigator 1 ModernaTX, Inc. $331.20 05/17/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253149
Principal investigator 1 ModernaTX, Inc. $21,910.00 05/17/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253161
Principal investigator 1 ModernaTX, Inc. $17,760.00 05/17/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253261
Principal investigator 1 ModernaTX, Inc. $9,600.00 05/17/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253321
Principal investigator 1 ModernaTX, Inc. $4,725.00 05/17/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253553
Principal investigator 1 ModernaTX, Inc. $96.60 05/17/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041253665
Principal investigator 1 ModernaTX, Inc. $51.35 05/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041248097
Principal investigator 1 SANOFI PASTEUR INC. $6,875.00 05/11/2023 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1035893347
Principal investigator 1 SANOFI PASTEUR INC. $75,283.02 05/11/2023 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1035893359
Principal investigator 1 Bavarian Nordic A/S $14,581.02 05/09/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC
Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults 65 Years No dispute reported 06/30/2026 988694705
Principal investigator 1 ModernaTX, Inc. $1,340.00 05/08/2023 Non-covered Recipient Entity
CLINICAL BIOSAFETY SERVICES
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1042060355
Principal investigator 1 GlaxoSmithKline, LLC. $91.53 05/05/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
A PHASE 1, SINGLE-BLIND, SAFETY, REACTOGENICITY, AND IMMUNOGENICITY TR No dispute reported 06/30/2026 1006174369
Principal investigator 1 GlaxoSmithKline, LLC. $4,540.02 05/05/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
A PHASE 1, SINGLE-BLIND, SAFETY, REACTOGENICITY, AND IMMUNOGENICITY TR No dispute reported 06/30/2026 1006174843
Principal investigator 1 GlaxoSmithKline, LLC. $256.32 05/05/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
A PHASE 1, SINGLE-BLIND, SAFETY, REACTOGENICITY, AND IMMUNOGENICITY TR No dispute reported 06/30/2026 1006174853
Principal investigator 1 ModernaTX, Inc. $6,995.00 05/02/2023 Non-covered Recipient Entity
CLINICAL BIOSAFETY SERVICES
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1042060293
Principal investigator 1 ModernaTX, Inc. $589.95 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252051
Principal investigator 1 ModernaTX, Inc. $589.95 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252066
Principal investigator 1 ModernaTX, Inc. $589.95 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252081
Principal investigator 1 ModernaTX, Inc. $589.95 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252097
Principal investigator 1 ModernaTX, Inc. $589.95 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252111
Principal investigator 1 ModernaTX, Inc. $589.95 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252125
Principal investigator 1 ModernaTX, Inc. $589.95 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252139
Principal investigator 1 ModernaTX, Inc. $589.95 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252153
Principal investigator 1 ModernaTX, Inc. $589.95 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252167
Principal investigator 1 ModernaTX, Inc. $589.95 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252181
Principal investigator 1 ModernaTX, Inc. $589.95 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252195
Principal investigator 1 ModernaTX, Inc. $589.95 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252209
Principal investigator 1 ModernaTX, Inc. $589.95 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252225
Principal investigator 1 ModernaTX, Inc. $589.95 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252239
Principal investigator 1 ModernaTX, Inc. $589.95 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252253
Principal investigator 1 ModernaTX, Inc. $589.95 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252268
Principal investigator 1 ModernaTX, Inc. $589.95 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252283
Principal investigator 1 ModernaTX, Inc. $589.95 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252297
Principal investigator 1 ModernaTX, Inc. $589.95 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252311
Principal investigator 1 ModernaTX, Inc. $589.95 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252325
Principal investigator 1 ModernaTX, Inc. $589.95 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252339
Principal investigator 1 ModernaTX, Inc. $498.17 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252353
Principal investigator 1 ModernaTX, Inc. $589.95 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252367
Principal investigator 1 ModernaTX, Inc. $589.95 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252381
Principal investigator 1 ModernaTX, Inc. $589.95 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252395
Principal investigator 1 ModernaTX, Inc. $589.95 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252409
Principal investigator 1 ModernaTX, Inc. $589.95 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252423
Principal investigator 1 ModernaTX, Inc. $589.95 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252437
Principal investigator 1 ModernaTX, Inc. $589.95 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252453
Principal investigator 1 ModernaTX, Inc. $589.95 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252467
Principal investigator 1 ModernaTX, Inc. $589.95 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252481
Principal investigator 1 ModernaTX, Inc. $589.95 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252493
Principal investigator 1 ModernaTX, Inc. $589.95 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252507
Principal investigator 1 ModernaTX, Inc. $589.95 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252523
Principal investigator 1 ModernaTX, Inc. $589.95 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252537
Principal investigator 1 ModernaTX, Inc. $589.95 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252551
Principal investigator 1 ModernaTX, Inc. $589.95 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252563
Principal investigator 1 ModernaTX, Inc. $589.95 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252579
Principal investigator 1 ModernaTX, Inc. $589.95 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252593
Principal investigator 1 ModernaTX, Inc. $589.95 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252607
Principal investigator 1 ModernaTX, Inc. $589.95 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252621
Principal investigator 1 ModernaTX, Inc. $589.95 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252637
Principal investigator 1 ModernaTX, Inc. $589.95 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252651
Principal investigator 1 ModernaTX, Inc. $589.95 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252665
Principal investigator 1 ModernaTX, Inc. $589.95 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252681
Principal investigator 1 ModernaTX, Inc. $589.95 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252695
Principal investigator 1 ModernaTX, Inc. $589.95 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252711
Principal investigator 1 ModernaTX, Inc. $589.95 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252727
Principal investigator 1 ModernaTX, Inc. $589.95 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252739
Principal investigator 1 ModernaTX, Inc. $589.95 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252755
Principal investigator 1 ModernaTX, Inc. $589.95 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252769
Principal investigator 1 ModernaTX, Inc. $589.95 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252783
Principal investigator 1 ModernaTX, Inc. $589.95 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252797
Principal investigator 1 ModernaTX, Inc. $589.95 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252811
Principal investigator 1 ModernaTX, Inc. $589.95 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252825
Principal investigator 1 ModernaTX, Inc. $589.95 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252839
Principal investigator 1 ModernaTX, Inc. $589.95 04/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252853
Principal investigator 1 GlaxoSmithKline, LLC. $5,123.80 04/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
A PHASE 1, SINGLE-BLIND, SAFETY, REACTOGENICITY, AND IMMUNOGENICITY TR No dispute reported 06/30/2026 1006174863
Principal investigator 1 ModernaTX, Inc. $67,536.98 04/26/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1041268359
Principal investigator 1 SANOFI PASTEUR INC. $6,345.69 04/25/2023 Non-covered Recipient Entity
Suncoast Research Associates Llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1035893163
Principal investigator 1 Bavarian Nordic A/S $45,706.70 04/21/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 988691025
Principal investigator 1 Bavarian Nordic A/S $57,640.74 04/21/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 988691031
Principal investigator 1 Janssen Pharmaceuticals, Inc $1,194.00 04/19/2023 Non-covered Recipient Entity
Suncoast Rsrch Associates Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986093559
Principal investigator 1 SANOFI PASTEUR INC. $149,522.18 04/18/2023 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1035893175
Principal investigator 1 Janssen Research & Development, LLC $4,800.00 04/10/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC
A Randomized, Double-blind Phase 3 Study to Assess the Immunogenicity and Safety of an Ad26.RSV.PreF-based Regimen at the End of Shelf-life in Adults Aged 60 to Less Than 65Years No dispute reported 06/30/2026 986144501
Principal investigator 1 ModernaTX, Inc. $204.00 04/10/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041562135
Principal investigator 1 SANOFI PASTEUR INC. $4,200.00 04/03/2023 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1035893187
Principal investigator 1 SANOFI PASTEUR INC. $21,482.48 04/03/2023 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1035893201
Principal investigator 1 ModernaTX, Inc. $25,865.17 03/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1041268345
Principal investigator 1 Bavarian Nordic A/S $142,424.20 03/22/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 988691019
Principal investigator 1 Janssen Pharmaceuticals, Inc $2,235.00 03/22/2023 Non-covered Recipient Entity
Suncoast Rsrch Associates Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986093557
Principal investigator 1 SANOFI PASTEUR INC. $79,128.61 03/22/2023 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older No dispute reported 06/30/2026 1035893123
Principal investigator 1 SANOFI PASTEUR INC. $750.00 03/22/2023 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older No dispute reported 06/30/2026 1035893297
Principal investigator 1 SANOFI PASTEUR INC. $7,900.00 03/22/2023 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older No dispute reported 06/30/2026 1035893321
Principal investigator 1 ModernaTX, Inc. $33.64 03/21/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041605529
Principal investigator 1 ModernaTX, Inc. $102.00 03/20/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1041605537
Principal investigator 1 GlaxoSmithKline, LLC. $2,483.71 03/17/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
A PHASE 1, SINGLE-BLIND, SAFETY, REACTOGENICITY, AND IMMUNOGENICITY TR No dispute reported 06/30/2026 1006174417
Principal investigator 1 GlaxoSmithKline, LLC. $183.09 03/17/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
A PHASE 1, SINGLE-BLIND, SAFETY, REACTOGENICITY, AND IMMUNOGENICITY TR No dispute reported 06/30/2026 1006174873
Principal investigator 1 GlaxoSmithKline, LLC. $333.18 03/17/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
A PHASE 1, SINGLE-BLIND, SAFETY, REACTOGENICITY, AND IMMUNOGENICITY TR No dispute reported 06/30/2026 1006174895
Principal investigator 1 GlaxoSmithKline, LLC. $3,884.57 03/17/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
A PHASE 1, SINGLE-BLIND, SAFETY, REACTOGENICITY, AND IMMUNOGENICITY TR No dispute reported 06/30/2026 1006174915
Principal investigator 1 SANOFI PASTEUR INC. $656,453.20 03/17/2023 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1035893109
Principal investigator 1 SANOFI PASTEUR INC. $3,375.00 03/16/2023 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1035892217
Principal investigator 1 SANOFI PASTEUR INC. $28,323.72 03/16/2023 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1035892243
Principal investigator 1 SANOFI PASTEUR INC. $2,500.00 03/16/2023 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1035892255
Principal investigator 1 SANOFI PASTEUR INC. $10,500.00 03/16/2023 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1035892267
Principal investigator 1 SANOFI PASTEUR INC. $1,200.00 03/16/2023 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1035892290
Principal investigator 1 SANOFI PASTEUR INC. $3,950.00 03/16/2023 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1035892303
Principal investigator 1 SANOFI PASTEUR INC. $25,094.34 03/16/2023 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1035892315
Principal investigator 1 Emergent BioSolutions Inc. $33,030.00 03/15/2023 Non-covered Recipient Entity
Suncoast Research Associates, LLC
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 No dispute reported 06/30/2026 1042864283
Principal investigator 1 ModernaTX, Inc. $166.50 03/14/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041562067
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251127
Principal investigator 1 ModernaTX, Inc. $15.73 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251141
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251157
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251169
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251183
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251198
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251215
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251229
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251243
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251257
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251271
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251285
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251299
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251313
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251327
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251341
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251355
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251371
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251385
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251397
Principal investigator 1 ModernaTX, Inc. $15.73 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251413
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251429
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251443
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251459
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251473
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251487
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251501
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251513
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251527
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251537
Principal investigator 1 ModernaTX, Inc. $15.73 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251555
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251567
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251579
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251595
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251609
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251625
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251635
Principal investigator 1 ModernaTX, Inc. $1,013.40 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251651
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251667
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251681
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251695
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251709
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251723
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251737
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251753
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251767
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251783
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251797
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251813
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251827
Principal investigator 1 ModernaTX, Inc. $15.73 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251841
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251855
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251869
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251883
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251897
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251909
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251923
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251939
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251953
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251967
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251981
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251995
Principal investigator 1 ModernaTX, Inc. $15.73 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252009
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252023
Principal investigator 1 ModernaTX, Inc. $589.95 03/13/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041252037
Principal investigator 1 GlaxoSmithKline, LLC. $40,265.60 03/03/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
A PHASE III, RANDOMIZED, OPEN-LABEL, CONTROLLED, MULTI-CENTER STUDY TO No dispute reported 06/30/2026 1006174429
Principal investigator 1 ModernaTX, Inc. $50,652.30 03/03/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1041268331
Principal investigator 1 Bavarian Nordic A/S $141,335.81 03/01/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 988690993
Principal investigator 1 Bavarian Nordic A/S $32,494.45 03/01/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 988690999
Principal investigator 1 Bavarian Nordic A/S $52,016.55 03/01/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 988691007
Principal investigator 1 Bavarian Nordic A/S $67,040.61 03/01/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 988691013
Principal investigator 1 ModernaTX, Inc. $18,225.00 03/01/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1041268317
Principal investigator 1 GlaxoSmithKline, LLC. $5,635.12 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
A PHASE 1, SINGLE-BLIND, SAFETY, REACTOGENICITY, AND IMMUNOGENICITY TR No dispute reported 06/30/2026 1006174331
Principal investigator 1 GlaxoSmithKline, LLC. $9,801.07 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
A PHASE 1, SINGLE-BLIND, SAFETY, REACTOGENICITY, AND IMMUNOGENICITY TR No dispute reported 06/30/2026 1006174345
Principal investigator 1 GlaxoSmithKline, LLC. $268.89 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
A PHASE 1, SINGLE-BLIND, SAFETY, REACTOGENICITY, AND IMMUNOGENICITY TR No dispute reported 06/30/2026 1006174405
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249641
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249653
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249667
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249683
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249699
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249713
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249725
Principal investigator 1 ModernaTX, Inc. $15.73 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249739
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249755
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249767
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249783
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249797
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249811
Principal investigator 1 ModernaTX, Inc. $544.06 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249825
Principal investigator 1 ModernaTX, Inc. $544.06 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249839
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249853
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249867
Principal investigator 1 ModernaTX, Inc. $635.84 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249881
Principal investigator 1 ModernaTX, Inc. $544.06 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249895
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249911
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249925
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249939
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249953
Principal investigator 1 ModernaTX, Inc. $15.73 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249967
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249981
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249995
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250009
Principal investigator 1 ModernaTX, Inc. $544.06 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250023
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250037
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250051
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250065
Principal investigator 1 ModernaTX, Inc. $1,013.40 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250085
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250099
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250113
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250127
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250143
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250159
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250177
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250189
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250205
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250219
Principal investigator 1 ModernaTX, Inc. $15.73 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250233
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250247
Principal investigator 1 ModernaTX, Inc. $15.73 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250261
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250275
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250289
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250305
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250319
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250333
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250347
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250359
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250375
Principal investigator 1 ModernaTX, Inc. $1,013.40 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250389
Principal investigator 1 ModernaTX, Inc. $544.06 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250403
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250417
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250433
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250447
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250461
Principal investigator 1 ModernaTX, Inc. $15.73 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250475
Principal investigator 1 ModernaTX, Inc. $635.84 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250491
Principal investigator 1 ModernaTX, Inc. $544.06 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250505
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250519
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250535
Principal investigator 1 ModernaTX, Inc. $544.06 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250551
Principal investigator 1 ModernaTX, Inc. $15.73 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250565
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250579
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250593
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250607
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250621
Principal investigator 1 ModernaTX, Inc. $544.06 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250635
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250649
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250661
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250675
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250691
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250705
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250719
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250733
Principal investigator 1 ModernaTX, Inc. $544.06 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250747
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250761
Principal investigator 1 ModernaTX, Inc. $635.84 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250775
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250791
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250803
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250816
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250831
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250847
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250860
Principal investigator 1 ModernaTX, Inc. $15.73 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250873
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250887
Principal investigator 1 ModernaTX, Inc. $544.06 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250901
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250914
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250929
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250943
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250957
Principal investigator 1 ModernaTX, Inc. $544.06 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250971
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250985
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041250999
Principal investigator 1 ModernaTX, Inc. $544.06 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251013
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251027
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251041
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251055
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251071
Principal investigator 1 ModernaTX, Inc. $544.06 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251087
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251101
Principal investigator 1 ModernaTX, Inc. $589.95 02/24/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041251115
Principal investigator 1 Janssen Pharmaceuticals, Inc $3,636.00 02/23/2023 Non-covered Recipient Entity
Suncoast Rsrch Associates Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986093555
Principal investigator 1 Bavarian Nordic A/S $13,450.00 02/22/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 988690987
Principal investigator 1 ModernaTX, Inc. $295.80 02/22/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1041268303
Principal investigator 1 Bavarian Nordic A/S $136,546.63 02/15/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 988690969
Principal investigator 1 Bavarian Nordic A/S $2,000.00 02/15/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 988690975
Principal investigator 1 Bavarian Nordic A/S $3,000.00 02/15/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 988690981
Principal investigator 1 GlaxoSmithKline, LLC. $163,246.00 02/15/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
A PHASE 1, SINGLE-BLIND, SAFETY, REACTOGENICITY, AND IMMUNOGENICITY TR No dispute reported 06/30/2026 1006174883
Principal investigator 1 Bavarian Nordic A/S $62,156.89 02/10/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 988690961
Principal investigator 1 ModernaTX, Inc. $2,000.00 02/10/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1041268259
Principal investigator 1 ModernaTX, Inc. $660.00 02/10/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1041268273
Principal investigator 1 ModernaTX, Inc. $35,120.84 02/10/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1041268285
Principal investigator 1 ModernaTX, Inc. $118,607.22 02/08/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults 50 Years of Age No dispute reported 06/30/2026 1041268243
Principal investigator 1 Bavarian Nordic A/S $78,806.24 02/01/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 988690955
Principal investigator 1 Bavarian Nordic A/S $3,828.12 01/27/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 988690949
Principal investigator 1 Janssen Pharmaceuticals, Inc $3,801.00 01/25/2023 Non-covered Recipient Entity
Suncoast Rsrch Associates Llc
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986093553
Principal investigator 1 Emergent BioSolutions Inc. $27,292.60 01/18/2023 Non-covered Recipient Entity
Suncoast Research Associates, LLC
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 No dispute reported 06/30/2026 1042864291
Principal investigator 1 ModernaTX, Inc. $15.73 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041247813
Principal investigator 1 ModernaTX, Inc. $15.73 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041247825
Principal investigator 1 ModernaTX, Inc. $15.73 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041247839
Principal investigator 1 ModernaTX, Inc. $635.84 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041247853
Principal investigator 1 ModernaTX, Inc. $15.73 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041247867
Principal investigator 1 ModernaTX, Inc. $15.73 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041247881
Principal investigator 1 ModernaTX, Inc. $544.06 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041247894
Principal investigator 1 ModernaTX, Inc. $15.73 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041247911
Principal investigator 1 ModernaTX, Inc. $1,013.40 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041247925
Principal investigator 1 ModernaTX, Inc. $544.06 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041247941
Principal investigator 1 ModernaTX, Inc. $544.06 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041247953
Principal investigator 1 ModernaTX, Inc. $1,013.40 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041247967
Principal investigator 1 ModernaTX, Inc. $544.06 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041247983
Principal investigator 1 ModernaTX, Inc. $544.06 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041247997
Principal investigator 1 ModernaTX, Inc. $635.84 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248009
Principal investigator 1 ModernaTX, Inc. $544.06 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248025
Principal investigator 1 ModernaTX, Inc. $544.06 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248039
Principal investigator 1 ModernaTX, Inc. $3,715.65 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248053
Principal investigator 1 ModernaTX, Inc. $15.73 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248068
Principal investigator 1 ModernaTX, Inc. $15.73 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248083
Principal investigator 1 ModernaTX, Inc. $544.06 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248243
Principal investigator 1 ModernaTX, Inc. $544.06 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248257
Principal investigator 1 ModernaTX, Inc. $15.73 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248271
Principal investigator 1 ModernaTX, Inc. $544.06 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248285
Principal investigator 1 ModernaTX, Inc. $544.06 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248299
Principal investigator 1 ModernaTX, Inc. $544.06 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248313
Principal investigator 1 ModernaTX, Inc. $3,715.65 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248327
Principal investigator 1 ModernaTX, Inc. $15.73 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248341
Principal investigator 1 ModernaTX, Inc. $15.73 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248355
Principal investigator 1 ModernaTX, Inc. $3,715.65 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248369
Principal investigator 1 ModernaTX, Inc. $544.06 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248383
Principal investigator 1 ModernaTX, Inc. $15.73 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248395
Principal investigator 1 ModernaTX, Inc. $3,715.65 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248409
Principal investigator 1 ModernaTX, Inc. $15.73 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248423
Principal investigator 1 ModernaTX, Inc. $544.06 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248439
Principal investigator 1 ModernaTX, Inc. $544.06 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248453
Principal investigator 1 ModernaTX, Inc. $15.73 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248467
Principal investigator 1 ModernaTX, Inc. $15.73 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248482
Principal investigator 1 ModernaTX, Inc. $1,013.40 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248497
Principal investigator 1 ModernaTX, Inc. $15.73 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248511
Principal investigator 1 ModernaTX, Inc. $15.73 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248525
Principal investigator 1 ModernaTX, Inc. $15.73 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248539
Principal investigator 1 ModernaTX, Inc. $15.73 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248553
Principal investigator 1 ModernaTX, Inc. $544.06 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248567
Principal investigator 1 ModernaTX, Inc. $544.06 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248581
Principal investigator 1 ModernaTX, Inc. $15.73 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248595
Principal investigator 1 ModernaTX, Inc. $15.73 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248609
Principal investigator 1 ModernaTX, Inc. $635.84 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248623
Principal investigator 1 ModernaTX, Inc. $544.06 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248637
Principal investigator 1 ModernaTX, Inc. $544.06 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248651
Principal investigator 1 ModernaTX, Inc. $544.06 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248665
Principal investigator 1 ModernaTX, Inc. $544.06 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248681
Principal investigator 1 ModernaTX, Inc. $544.06 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248693
Principal investigator 1 ModernaTX, Inc. $15.73 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248709
Principal investigator 1 ModernaTX, Inc. $635.84 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248723
Principal investigator 1 ModernaTX, Inc. $635.84 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248737
Principal investigator 1 ModernaTX, Inc. $635.84 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248751
Principal investigator 1 ModernaTX, Inc. $15.73 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248765
Principal investigator 1 ModernaTX, Inc. $544.06 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248779
Principal investigator 1 ModernaTX, Inc. $544.06 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248795
Principal investigator 1 ModernaTX, Inc. $544.06 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248809
Principal investigator 1 ModernaTX, Inc. $15.73 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248823
Principal investigator 1 ModernaTX, Inc. $15.73 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248837
Principal investigator 1 ModernaTX, Inc. $544.06 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248853
Principal investigator 1 ModernaTX, Inc. $15.73 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248867
Principal investigator 1 ModernaTX, Inc. $15.73 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248881
Principal investigator 1 ModernaTX, Inc. $15.73 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248895
Principal investigator 1 ModernaTX, Inc. $635.84 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248909
Principal investigator 1 ModernaTX, Inc. $544.06 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248923
Principal investigator 1 ModernaTX, Inc. $544.06 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248937
Principal investigator 1 ModernaTX, Inc. $15.73 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248951
Principal investigator 1 ModernaTX, Inc. $15.73 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248965
Principal investigator 1 ModernaTX, Inc. $15.73 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248979
Principal investigator 1 ModernaTX, Inc. $3,715.65 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041248991
Principal investigator 1 ModernaTX, Inc. $15.73 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249005
Principal investigator 1 ModernaTX, Inc. $15.73 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249021
Principal investigator 1 ModernaTX, Inc. $15.73 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249035
Principal investigator 1 ModernaTX, Inc. $15.73 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249043
Principal investigator 1 ModernaTX, Inc. $544.06 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249057
Principal investigator 1 ModernaTX, Inc. $544.06 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249071
Principal investigator 1 ModernaTX, Inc. $635.84 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249085
Principal investigator 1 ModernaTX, Inc. $544.06 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249099
Principal investigator 1 ModernaTX, Inc. $635.84 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249113
Principal investigator 1 ModernaTX, Inc. $544.06 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249127
Principal investigator 1 ModernaTX, Inc. $635.84 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249143
Principal investigator 1 ModernaTX, Inc. $15.73 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249157
Principal investigator 1 ModernaTX, Inc. $15.73 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249173
Principal investigator 1 ModernaTX, Inc. $544.06 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249187
Principal investigator 1 ModernaTX, Inc. $15.73 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249201
Principal investigator 1 ModernaTX, Inc. $15.73 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249217
Principal investigator 1 ModernaTX, Inc. $15.73 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249229
Principal investigator 1 ModernaTX, Inc. $544.06 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249241
Principal investigator 1 ModernaTX, Inc. $15.73 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249253
Principal investigator 1 ModernaTX, Inc. $15.73 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249271
Principal investigator 1 ModernaTX, Inc. $544.06 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249287
Principal investigator 1 ModernaTX, Inc. $635.84 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249301
Principal investigator 1 ModernaTX, Inc. $544.06 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249315
Principal investigator 1 ModernaTX, Inc. $544.06 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249329
Principal investigator 1 ModernaTX, Inc. $635.84 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249343
Principal investigator 1 ModernaTX, Inc. $15.73 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249357
Principal investigator 1 ModernaTX, Inc. $3,715.65 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249373
Principal investigator 1 ModernaTX, Inc. $544.06 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249387
Principal investigator 1 ModernaTX, Inc. $15.73 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249401
Principal investigator 1 ModernaTX, Inc. $544.06 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249415
Principal investigator 1 ModernaTX, Inc. $15.73 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249427
Principal investigator 1 ModernaTX, Inc. $635.84 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249443
Principal investigator 1 ModernaTX, Inc. $635.84 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249457
Principal investigator 1 ModernaTX, Inc. $15.73 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249471
Principal investigator 1 ModernaTX, Inc. $544.06 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249485
Principal investigator 1 ModernaTX, Inc. $15.73 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249497
Principal investigator 1 ModernaTX, Inc. $15.73 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249511
Principal investigator 1 ModernaTX, Inc. $544.06 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249527
Principal investigator 1 ModernaTX, Inc. $544.06 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249543
Principal investigator 1 ModernaTX, Inc. $635.84 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249557
Principal investigator 1 ModernaTX, Inc. $15.73 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249571
Principal investigator 1 ModernaTX, Inc. $15.73 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249585
Principal investigator 1 ModernaTX, Inc. $15.73 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249601
Principal investigator 1 ModernaTX, Inc. $544.06 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249613
Principal investigator 1 ModernaTX, Inc. $15.73 01/12/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1041249629
Principal investigator 1 GlaxoSmithKline, LLC. $4,063.99 01/11/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
A PHASE 1, SINGLE-BLIND, SAFETY, REACTOGENICITY, AND IMMUNOGENICITY TR No dispute reported 06/30/2026 1006174832
Principal investigator 1 Vertex Pharmaceuticals Incorporated $187,756.79 01/02/2023 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN) No dispute reported 06/30/2026 1006169003